EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exploring the Impact of TP53 Mutation and Wild-Type Status on the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer

Alexander Yakobson, Ronen Brenner, Itamar Gothelf, Natalie Maimon Rabinovich iD, Ahron Yehonatan Cohen, Ashraf Abu Jama, Nashat Abu Yasin, Fahmi Abu Ghalion iD, Abed Agbarya iD, Walid Shalata iD

International Journal of Molecular Sciences · 19.07.2025 · 26 (14) · 6939

DOI: 10.3390/ijms26146939 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.07.2025. Verfasst von Alexander Yakobson und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Legacy Heritage Cancer Center, Dr. Larry Norton Institute, Soroka Medical Center, Beer Sheva 84105, Israel. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Mutation, Tumor Suppressor Protein p53. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TP (tumor protein) 53 mutation status plays a critical role in cancer progression and may influence survival outcomes in non-small cell lung cancer (NSCLC) patients receiving immunotherapy. This study investigates the impact of TP53 mutation status and immunotherapy treatment on survival in NSCLC patients. This retrospective study analyzed NSCLC patients treated with pembrolizumab or ipilimumab plus nivolumab, stratified by TP53 mutation status and PD-L1 (programmed death-ligand 1) expression (50%). Survival outcomes (overall survival (OS) and progression free survival (PFS) were assessed using Kaplan–Meier curves and log-rank tests, with subgroup analysis by histological subtype. In squamous cell cancer (SCC) patients, no significant differences in OS or PFS were found based on TP53 mutation status or treatment type. A trend toward improved survival was observed with pembrolizumab (p = 0.088). In adenocarcinoma patients, significant differences in OS and PFS were observed based on TP53 mutation status. Pembrolizumab showed superior survival outcomes compared to ipilimumab plus nivolumab in TP53 wild-type patients (p < 0.001). PD-L1 ≥ 1% also predicted better outcomes, especially in adenocarcinoma patients. TP53 mutation status and immunotherapy type significantly influence survival outcomes in NSCLC, particularly in adenocarcinoma patients. Pembrolizumab demonstrated superior efficacy in TP53 wild-type patients, with PD-L1 expression further refining survival predictions. These findings underscore the importance of personalized treatment strategies based on TP53 status and PD-L1 expression in NSCLC. Further studies are needed to validate these results and optimize treatment approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsMutationTumor Suppressor Protein p53ImmunotherapyHumansMaleFemaleMiddle AgedAgedAntibodies, Monoclonal, HumanizedNivolumabRetrospective StudiesIpilimumabB7-H1 AntigenAdultAged, 80 and overTreatment OutcomeKaplan-Meier Estimate

Stichwörter der Autor:innen

NSCLCimmunotherapylung cancerreal-world evidencetumor protein P53 (TP53)

Substanzen

Tumor Suppressor Protein p53pembrolizumabAntibodies, Monoclonal, HumanizedNivolumabTP53 protein, humanIpilimumabB7-H1 AntigenCD274 protein, human

Autor:innen und Institutionen

  • The Legacy Heritage Cancer Center, Dr. Larry Norton Institute, Soroka Medical Center, Beer Sheva 84105, Israel.
  • Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva 84105, Israel.
  • Edith Wolfson Medical Center, Oncology Institute, Holon 58220, Israel.
  • Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.
  • Goldman Medical School, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva 84105, Israel.
  • Department of Oncology, Meir Medical Center, Kfar Saba 44180, Israel.

ORCID-Profile: Natalie Maimon Rabinovich, Fahmi Abu Ghalion, Abed Agbarya, Walid Shalata

Zitieren

APA

Yakobson, A., Brenner, R., Gothelf, I., Maimon Rabinovich, N., Cohen, A. Y., Abu Jama, A., Abu Yasin, N., Abu Ghalion, F., Agbarya, A., & Shalata, W. (2025). Exploring the Impact of TP53 Mutation and Wild-Type Status on the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 26(14), 6939. https://doi.org/10.3390/ijms26146939

Vancouver

Yakobson A, Brenner R, Gothelf I, Maimon Rabinovich N, Cohen AY, Abu Jama A, et al. Exploring the Impact of TP53 Mutation and Wild-Type Status on the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences. 2025;26(14):6939. doi:10.3390/ijms26146939

BibTeX
@article{Yakobson2025,
  author = {Yakobson, Alexander and Brenner, Ronen and Gothelf, Itamar and Maimon Rabinovich, Natalie and Cohen, Ahron Yehonatan and Abu Jama, Ashraf and Abu Yasin, Nashat and Abu Ghalion, Fahmi and Agbarya, Abed and Shalata, Walid},
  title = {Exploring the Impact of TP53 Mutation and Wild-Type Status on the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {14},
  pages = {6939},
  doi = {10.3390/ijms26146939}
}
Kostenlos starten →